France's GenSight Biologics 2025 net loss narrows on reduced R&D spending

Gensight Biologics SA

27/03/2026 06:44

Overview

France biopharma's 2025 revenue and operating income fell sharply yr/yr

Net loss narrowed to EUR 12 mln, with EPS at EUR -0.08

Company warns of material uncertainty over going concern due to need for further funding

Outlook

GenSight projects cash runway to extend through December 2026

Company expects 2026 early access program revenues to cover operating expenses, excluding Phase III trial costs

GenSight says additional funding or partnerships needed before end-2026 to avoid delaying Phase III trial

Result Drivers

LOWER RESEARCH TAX CREDIT - Operating income fell mainly due to a decrease in the research tax credit, reflecting reduced clinical development expenses for GS010

REDUCED R&D SPENDING - Research and development expenses dropped as the company focused on prioritizing activities and reduced spending related to GS010 technology transfer and study preparation

COST DISCIPLINE - Sales, marketing, and administrative expenses declined due to ongoing cost control, with professional fees falling despite increased personnel costs

Company press release: ID:nBw98kdTNa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-EUR 0.08
FY Net Income
-EUR 12 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Gensight Biologics SA is €0.31, about 246.6% above its March 26 closing price of €0.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)